Market penetration is improving through awareness campaigns and professional education
Additionally, GLP-1RAs were recognised for their remarkably significant impact on weight reduction in both diabetic and non-diabetic overweight and obese patients (30)
"These drugs help over 50 percent of people lose up to 25 percent of their body weight," said Dr
In a Phase 2 obesity trial of retatrutide published in the New England Journal of Medicine in 2023, nausea, diarrhea, vomiting and constipation were cited as the most common adverse events, with higher doses associated with more severe problems
Magnesium deficiency manifests as confusion, disorientation, personality changes, loss of appetite, depression, muscle cramps, tingling, numbness, hypertension, cardiac dysrhythmia, seizures